 |
SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of...
Marketing automation is a necessary component of modern engagement with customers. Automated emails, triggered campaigns, lead nurturing and lifecycle messaging enable brands to scale their messagin...
Daily Bulletin
Modern electrical systems require reliable protection for wiring and cables to ensure safety, durability, and long-term performance. In residential, commercial, and industrial environments, conduits a...
Daily Bulletin
There's perhaps no more challenging project for an international enterprise to pursue than a global product launch campaign. At the same time, various regions, languages, compliance standards, digit...
Daily Bulletin
